An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
This is a multicenter, open-label, global study that will enroll patients who are currently receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or in combination with any other approved or investigational anticancer agents, in an eligible AstraZeneca/MedImmune-sponsored clinical study.
Inclusion Criteria:
Exclusion Criteria:
The following exclusion criteria apply only to patients receiving treatment or retreatment:
Holargos, Athens, 155 62, Greece
Isehara-shi, 259-1193, Japan
Izumi-shi, 594-0073, Japan
Kishiwada-shi, 596-8501, Japan
Nagaoka-shi, 940-2085, Japan
Suita-shi, 565-0871, Japan
Sunto-gun, 411-8777, Japan
pos.Pesochnyi, 197758, Russia
Gyeongsangnam-do, 52727, South Korea
Chernivtsі, 58013, Ukraine